Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
9.04
-0.03 (-0.33%)
Oct 10, 2025, 1:20 PM EDT - Market open
Mersana Therapeutics Analyst Ratings
Total Analysts
3
Consensus Rating
Strong Buy
Price Target
$33.00
Upside
+265.04%
Ratings History
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Truist Securities | Truist Securities | Strong Buy Maintains $250 → $36 | Strong Buy | Maintains | $250 → $36 | +298.23% | Aug 14, 2025 |
Guggenheim | Guggenheim | Strong Buy Maintains $125 → $30 | Strong Buy | Maintains | $125 → $30 | +231.86% | Aug 14, 2025 |
Truist Securities | Truist Securities | Strong Buy Maintains $225 → $250 | Strong Buy | Maintains | $225 → $250 | +2,665.49% | May 16, 2025 |
Guggenheim | Guggenheim | Strong Buy Reiterates $125 | Strong Buy | Reiterates | $125 | +1,282.74% | May 16, 2025 |
William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 6, 2025 |
Citigroup | Citigroup | Strong Buy Maintains $150 → $125 | Strong Buy | Maintains | $150 → $125 | +1,282.74% | Aug 27, 2024 |
Baird | Baird | Hold Maintains $100 → $75 | Hold | Maintains | $100 → $75 | +729.65% | Aug 14, 2024 |
JP Morgan | JP Morgan | Sell → Hold Upgrades $125 | Sell → Hold | Upgrades | $125 | +1,282.74% | Mar 19, 2024 |
Wedbush | Wedbush | Hold → Buy Upgrades $50 → $175 | Hold → Buy | Upgrades | $50 → $175 | +1,835.84% | Feb 29, 2024 |
Truist Securities | Truist Securities | Hold → Strong Buy Upgrades $225 | Hold → Strong Buy | Upgrades | $225 | +2,388.94% | Feb 29, 2024 |
Baird | Baird | Hold Maintains $25 → $125 | Hold | Maintains | $25 → $125 | +1,282.74% | Feb 29, 2024 |
Guggenheim | Guggenheim | Hold → Strong Buy Upgrades $175 | Hold → Strong Buy | Upgrades | $175 | +1,835.84% | Feb 29, 2024 |
Citigroup | Citigroup | Hold → Strong Buy Upgrades $25 → $125 | Hold → Strong Buy | Upgrades | $25 → $125 | +1,282.74% | Dec 4, 2023 |
Citigroup | Citigroup | Strong Buy → Hold Downgrades $250 → $25 | Strong Buy → Hold | Downgrades | $250 → $25 | +176.55% | Jul 28, 2023 |
Baird | Baird | Buy → Hold Downgrades $175 → $25 | Buy → Hold | Downgrades | $175 → $25 | +176.55% | Jul 28, 2023 |
Wedbush | Wedbush | Buy → Hold Downgrades $300 → $50 | Buy → Hold | Downgrades | $300 → $50 | +453.10% | Jul 27, 2023 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.